Bidirectional relationships of comorbidity with obstructive sleep apnoea

Margaret Gleeson and Walter T. McNicholas

School of Medicine, University College Dublin, and Dept of Respiratory and Sleep Medicine, St. Vincent’s Hospital Group, Dublin, Ireland.

Corresponding author: Walter T. McNicholas (walter.mcNicholas@ucd.ie)

Obstructive sleep apnoea (OSA) is an independent risk factor for comorbidity, especially cardiometabolic. However, some comorbidities may be risk factors for OSA, supporting a bidirectional relationship that may have important implications for treatment. https://bit.ly/3BbJy6V

Cite this article as: Gleeson M, McNicholas WT. Bidirectional relationships of comorbidity with obstructive sleep apnoea. Eur Respir Rev 2022; 31: 210256 [DOI: 10.1183/16000617.0256-2021].

Abstract

Obstructive sleep apnoea (OSA) is frequently associated with comorbidities that include metabolic, cardiovascular, renal, pulmonary and neuropsychiatric. There is considerable evidence that OSA is an independent risk factor for many of these comorbidities but, more recently, there is evidence that some of these comorbidities may predispose to the development of OSA. Thus, there is growing evidence of a bidirectional relationship between OSA and comorbidity, especially for heart failure, metabolic syndrome and stroke. Potential mechanisms of bidirectional relationships differ in individual comorbidities with fluid retention and redistribution being especially important in heart failure and end-stage renal disease, whereas neural mechanisms may be more important in diabetes mellitus and stroke. The evidence for other comorbidities, such as hypertension and atrial fibrillation, support these being more a consequence of OSA with limited evidence to support a bidirectional relationship. The present review explores the evidence for such bidirectional relationships with a particular perspective on comorbidities that may predispose to OSA. The impact of therapy in bidirectional relationships is also reviewed, which highlights the clinical importance of accurate diagnosis. This aspect is especially true of COPD, where the identification of co-existing OSA has important implications for optimum therapy.

Introduction

Obstructive sleep apnoea (OSA) is highly prevalent [1] and there is growing evidence to support an independent association of OSA with a wide range of comorbidities including metabolic, cardiovascular, renal, pulmonary and neuropsychiatric [2]. The evidence is greater for some comorbidities than others, and, in cardiovascular disease, is strongest for hypertension and atrial fibrillation [3]. The demonstration of independent associations between OSA and comorbidity may be more difficult because of the very high prevalence of sleep-disordered breathing (SDB) in the general population, in addition to the confounding effect of shared risk factors such as obesity. Furthermore, there is evidence of a bidirectional relationship between OSA and several comorbidities that include heart failure (HF) as a result of nocturnal fluid accumulation in the neck, in addition to stroke and the metabolic syndrome.

Possible mechanisms relating to OSA contributing to comorbidity include intermittent hypoxia, fluctuating intrathoracic pressure and recurring micro-arousals that are integral features of obstructive apnoea, which generate cell and molecular consequences that include sympathetic excitation, systemic inflammation and oxidative stress, in addition to metabolic and endothelial dysfunction [4–7]. Different mechanisms may predominate in specific comorbidities. For example, sympathetic excitation appears to be the principal mechanism in the development of hypertension, especially nocturnal [8], whereas inflammation and oxidative stress are likely to be more important in the development of atherosclerosis and coronary artery disease [3]. Other factors such as obesity may be linked to both OSA and other comorbidities, especially

https://doi.org/10.1183/16000617.0256-2021
cardiometabolic, which confound the assessment of independent relationships between OSA and comorbidity [1]. Furthermore, there is evidence of interaction between the intermittent hypoxia that is a core feature of OSA and adipose tissue in the development of cardiometabolic comorbidity [9, 10].

The present review explores the relationships between OSA and comorbidity with a specific perspective on comorbidities that show evidence of a bidirectional relationship. Potential benefits of therapy will also be discussed, which have recently been questioned, especially relating to cardiovascular outcomes [11–13].

**Metabolic syndrome**

The metabolic syndrome includes systemic hypertension, insulin resistance, hyperlipidaemia and central obesity and has been linked to OSA [14, 15]. The relationship between OSA and the metabolic syndrome is complex and likely bidirectional in nature [7, 16]. OSA has been shown to cause or worsen several metabolic disorders, especially hypertension and insulin resistance [16], but several metabolic disorders predispose to OSA by mechanisms that include anatomic and neural effects on the upper airway [7].

**Obesity**

Many patients with OSA are obese and most research has focussed on obesity as a risk factor for OSA, although there are grounds to propose that the relationship is bidirectional.

**Obesity predisposing to OSA**

There is a strong link between OSA and obesity, and the contribution of central obesity to OSA and comorbidity occurs at several levels. The accumulation of fat in the neck contributes to oropharyngeal narrowing, which increases the collapsibility of the upper airway, and abdominal obesity reduces traction on the upper airway, further predisposing to increased collapsibility [17]. Furthermore, intermittent hypoxia, which is a central feature of OSA, elicits a pro-inflammatory response in visceral adipose tissue and contributes to insulin resistance [9]. In epidemiological terms, 70% of those with OSA are obese [18] and, conversely, 50% of those with a body mass index (BMI) >40 have OSA with an apnoea–hypopnoea index (AHI) >10 [19]. A higher BMI typically results in more severe OSA, most notably in males and in the younger population.

**Impact of therapy**

Major weight reduction, especially following bariatric surgery, improves OSA [20], whereas a recent report showed only modest benefit to OSA from weight loss by dietary intervention alone over a 10-year follow-up period [21]. Weight loss shows the highest benefit to OSA in patients with a small pre-existing maxillomandibular volume, indicating an important interaction between upper airway anatomy and the impact of obesity [22].

**OSA predisposing to obesity**

Although lifestyle effects of OSA, such as reduced activity levels and a tendency to snack with high calorie foods to boost energy, should promote weight gain, there has been limited research on this subject. Obese men with OSA lose less weight in response to a 1-year dietary and exercise programme compared with similarly obese men without OSA [23]. While continuous positive airway pressure (CPAP) therapy is highly effective in controlling OSA, paradoxically, some patients gain weight after commencing CPAP, especially females and nonobese patients [24].

Overall, the relationship between obesity and OSA is synergistic in terms of cardiometabolic risk with a variety of potential intermediate mechanisms including inflammation, endothelial dysfunction, and insulin resistance being amplified by the concurrence of both disorders [15].

**Diabetes mellitus**

Diabetes and OSA frequently coexist and there is growing evidence of a bidirectional relationship [7].

**OSA predisposing to diabetes**

There is growing evidence that OSA represents an independent risk factor for diabetes mellitus [25]. Several cross-sectional cohort studies have demonstrated an independent relationship with type 2 diabetes and insulin resistance, including the European Sleep Apnea Database (ESADA) [26, 27], and a pooled estimate of relative risk for diabetes from nine original studies was 1.69 (95% CI 1.45–1.80) [25]. Mechanisms of diabetes and insulin resistance include intermittent hypoxia and sleep fragmentation leading to sympathetic excitation and inflammation. There are fewer long-term studies on this risk. One community-based study of middle-aged men found an odds ratio for incident diabetes of 4.4 (95% CI 1.1–18.0) comparing those with and without OSA after 10-years follow-up after adjusting for confounders, and
AHI was inversely related to insulin sensitivity index at follow-up [28]. Another historical cohort study involving 8678 adults investigated for OSA reported that those with severe OSA had a 30% higher risk of developing diabetes than those without OSA after a mean follow-up of 67 months after controlling for confounding factors [29].

Impact of therapy

CHIRINOS et al. [30] reported that CPAP alone for 24 weeks did not benefit insulin sensitivity in nondiabetic patients with OSA in contrast to weight reduction. Randomised control studies of CPAP in diabetic patients with OSA have produced mixed results, some showing no benefit to diabetic control or insulin sensitivity, whereas others reported benefit [25]. Good compliance with CPAP was a factor in decreasing the risk of incident diabetes in a US Veterans Affairs study, despite weight gain during the follow-up period [31].

Diabetes predisposing to OSA

Some consequences of diabetes mellitus could predispose to OSA, including neuropathy affecting the upper airway muscles, and disturbances in ventilatory control. A retrospective primary care cohort study involving over 1 million subjects reported an adjusted incidence rate ratio of OSA in patients with type 2 diabetes compared with those without of 1.48 (95% CI 1.42–1.55; p<0.001), and identified insulin use, diabetic foot disease, male sex, obesity and cardiovascular disease as significant factors [32]. Another prospective study of almost 300,000 healthcare professionals found that OSA was an independent risk factor for incident diabetes, but conversely, insulin-dependent diabetes was an independent risk factor for OSA in women [33].

Thus, overall, there is good evidence for a bidirectional relationship between OSA and diabetes, but evidence of benefit from CPAP therapy to glycaemic control is limited.

Hypertension

While hypertension is very common in patients with OSA, the great majority of research on this topic has focussed on OSA as a risk factor for hypertension [34].

OSA predisposing to hypertension

There is strong evidence across many population-based epidemiological studies that OSA is a risk factor for systemic hypertension, often with a nondipping nocturnal blood pressure (BP) profile. Data from the Sleep Heart Health Study indicated a dose-dependent relationship with prevalent hypertension [35] and the Wisconsin Cohort study reported a higher presence of hypertension associated with OSA after 4 years follow-up [36]. A meta-analysis of seven prospective studies confirmed an independent relationship with incident hypertension in a dose-dependent fashion [37], particularly resulting in the loss of nocturnal dipping and high diastolic BP [38], as well as resistance to conventional antihypertensive treatment [39]. Indeed, nondipping nocturnal BP is highly predictive of OSA, independent of symptom profile [40], and rapid eye movement (REM)-associated OSA is independently associated with incident nondipping BP [41]. Sympathetic excitation appears to be the principal pathogenic mechanism [8, 42] with possible additional involvement of renin-angiotensin-aldosterone system (RAAS) dysfunction. Hypertension has also been associated with mild OSA. Data from the ESADA study involving 4372 subjects with mild OSA found an independent relationship with prevalent hypertension [43], and a prospective study involving 744 subjects with mild/moderate OSA and normotensive at baseline reported an association with incident hypertension after 9 years in subjects <60 years old [44].

Impact of therapy

While many studies indicate a reduction in BP with CPAP therapy, the effect is small at 2 mmHg in 24 h mean BP [45], although greater in younger subjects and those with uncontrolled hypertension or severe oxygen desaturation [46], and in more CPAP-compliant patients [47].

Hypertension predisposing to OSA

There is limited evidence that hypertension may predispose to OSA. Data from animal and small human studies suggest fluctuations in BP can influence upper airway tone by demonstrating inhibitory changes on electromyogram (EMG). This suggests that reduction in BP may improve airflow and reduce OSA severity [48]. Furthermore, a meta-analysis of 11 studies, including prospective and randomised trials, supports the concept that antihypertensives may reduce AHI, with a more pronounced effect when diuretics were used [49].
Heart failure
The bidirectional relationship between sleep apnoea and HF can be partly explained by shared risk factors including age, high BMI and sedentary lifestyle. Unifying mechanisms, particularly fluid retention and redistribution, result in a bidirectional relationship where it may be difficult to establish cause and effect [50]. HF is associated with both central and obstructive sleep apnoea, but for the purpose of this review, only the relationship with OSA will be discussed.

**OSA predisposing to HF**
Despite shared risk factors, large scale epidemiological studies have reported that OSA is independently associated with an increased risk of incidence and progression of coronary heart disease, congestive HF and cardiovascular mortality [51]. In the Sleep Heart Health Study, 4442 patients were followed prospectively and demonstrated a 58% increased risk of incident HF in those with severe OSA (AHI>30) compared with those without OSA [52], and the severity of OSA was directly proportional to incident HF risk.

Obstructive events lead to major swings in intrathoracic pressure, which alter cardiac haemodynamics resulting in increased preload, reduced left ventricular filling pressure, and increased afterload [17]. These effects stimulate the RAAS promoting sodium and water retention [53]. OSA may induce cardiac remodelling, contributing to HF, and may acutely impair cardiac function, thus worsening episodes of acute HF [54]. Patients with a higher AHI exhibit a greater degree of diastolic dysfunction [55].

Patients with no or mild OSA had a 50% less incidence of fatal events compared with those with untreated moderate or severe disease [56]. OSA can negatively impact the prognosis of HF and is associated with increased hospital readmissions and an increased rate of post-discharge mortality in patients diagnosed with OSA as an inpatient [57].

**Impact of therapy**
Treatment of OSA with CPAP improves intermediate cardiovascular end-points such as BP, heart rate and rhythm, and ejection fraction [58]. KANEKO et al. [59] found a 9% increase in left ventricular ejection fraction (LVEF) in addition to a daytime fall in heart rate and BP, which may reflect a reduction in nocturnal urinary excretion of epinephrine. However, while immediate physiological improvement has been shown with CPAP therapy, long-term reports on the benefit of CPAP have been inconsistent. Data supporting improved mortality and transplant free survival are lacking [60]. Studies have been limited by small sample sizes and short follow-up periods. Observational studies of long-term CPAP therapy have reported reduced cardiovascular morbidity and mortality over 10 years’ follow-up compared with those who were noncompliant with CPAP [61, 62]. However, more recent randomised controlled trials of CPAP therapy such as the SAVE trial have failed to show benefits in the secondary prevention of cardiovascular diseases, including HF, although the study was limited to nonsleepy patients with OSA and compliance with CPAP was poor [63].

**HF predisposing to OSA**
Many observational studies have demonstrated a higher prevalence of SDB in HF than those without [50]. However, patients with HF and OSA report less hypersomnolence, thus making it harder to recognise [64]. In an outpatient clinic setting, 53% of patients with stable HF met the diagnostic criteria for OSA [64] and the degree of cardiac dysfunction relates to the severity of OSA [54]. A prospective study of 203 HF patients with LVEF <40% reported 71% having AHI ≥10 and 43% meeting the clinical diagnostic criteria for OSA [65].

A different clinical phenotype of OSA is common in patients with HF, with many having lower BMI, which supports the view that HF may predispose to, or exacerbate SDB, in the absence of other shared risk factors such as obesity [54]. Patients with HF have a lower stroke volume, which, through neurogenic and humoral mechanisms, promotes fluid retention. Nocturnal redistribution of fluid in the recumbent position to dependent areas of the body such as the parapharyngeal soft tissue increases upper airway resistance and collapsibility [66]. Dietary sodium intake is directly proportional to the severity of OSA in HF, likely due to effects on fluid retention and redistribution [67]. Furthermore, nonobese men with venous insufficiency who wore compression stockings during the day to prevent fluid accumulation showed a reduction in AHI of 36% compared with no stockings [68]. A schematic representation of factors associated with fluid retention and redistribution to the neck region that predispose to pharyngeal collapse is given in figure 1.
Impact of therapy
As the severity of OSA can fluctuate in response to the degree of fluid redistribution, it is plausible to propose that OSA should respond to treatment of HF. However, in a randomised control trial (RCT) of patients with severe OSA, sodium restriction and diuretic therapy resulted in only a limited improvement in AHI, suggesting that fluid accumulation only partially explains the aetiology of OSA in HF [69]. In an acute exacerbation of hypertensive diastolic HF, diuretic therapy resulted in a reduction in body weight, increased pharyngeal calibre, and a fall of 17 in AHI [70]. Conversely, in an observational study, diuretic therapy improved OSA in overweight patients or those with hypertension but no significant improvement was seen in OSA severity in patients with HF [71]. While beneficial in central sleep apnoea, cardiac resynchronisation therapy has been little studied in OSA, although in small sample sizes has been reported to reduce AHI [72].

Renal dysfunction
Current evidence suggests that renal disease and sleep apnoea have a bidirectional relationship. Patients with renal impairment have an increased risk of SDB, with both OSA and central sleep apnoea (CSA) more common than in those with normal renal function, independent of confounders [73]. End-stage renal disease (ESRD) can also lead to worsening of OSA. It is increasingly recognised that OSA increases the risk of kidney injury and is associated with progressive decline in renal function [74].

Renal disease predisposing to OSA
The prevalence of OSA is up to ten times higher in patients with chronic kidney disease (CKD) than in the general population [75] but OSA remains under-recognised in CKD, which may reflect atypical presentations and a higher threshold for symptom recognition. The occurrence of OSA increases proportionally to the severity of CKD, supporting its role in pathogenesis. A clinic-based study reported a prevalence for OSA of 27%, 41% and 57% in patients with eGFR >60, patients with eGFR <60 but not on renal replacement therapy, and those on haemodialysis respectively [76].

Factors contributing to OSA in CKD include increased chemoreflex sensitivity, reduced clearance of uraemic toxins, and hypervolaemia [77]. Changes in chemoreflex responsiveness in response to metabolic acidosis in ESRD can enhance the responsiveness to carbon dioxide tension ($P_{CO2}$), thus affecting ventilation and the apnoeic threshold. Accumulation of uraemic toxins and related myopathy can increase upper airway collapsibility [77]. AHI scores correlate negatively with urea and peritoneal creatinine suggesting improved uraemic clearance can improve symptoms. Fluid accumulation with associated nocturnal redistribution in the recumbent position with consequent pharyngeal narrowing, as with HF, is also likely to play an important role (figure 1). In a group of 40 patients on haemodialysis, 70% had an AHI >15 as well as a greater total body extracellular fluid volume, including neck, thorax and leg volumes despite no difference in BMI compared with those with an AHI <5 [78].

Impact of therapy
Increased fluid overload predicts a worsening of OSA and aggressive treatment of ESRD may reduce the severity. Daily dialysis, nocturnal dialysis and nocturnal peritoneal automated dialysis have been addressed in observational studies with benefits to OSA associated with reduced AHI, reduced airway congestion,
and improved uraemic clearance [79, 80]. Additional removal of 2.2 L of fluid during a single ultrafiltration session induced a 36% reduction in AHI that correlated with the amount of fluid removed [81]. Renal transplantation reverses many of the metabolic complications in ESRD and slows the progression of associated comorbidities but its role in benefiting OSA remains inconclusive. In one report, 18 patients with ESRD having polysomnography (PSG) before and 3 months after transplantation demonstrated a significant improvement in the prevalence and severity of OSA after surgery [82].

**OSA predisposing to renal disease**

While OSA can occur as a result of CKD, there is evidence that OSA can contribute to CKD and progressive decline in GFR [83]. OSA has also been associated with a higher morbidity and mortality in patients with ESRD, which may relate to the compounding effects of comorbidities such as cardiovascular and cerebrovascular disease, including dysrhythmia, coronary disease and stroke. However, retrospective data analysis from the Wisconsin Sleep Cohort reported that OSA did not accelerate kidney function decline over time compared with those without OSA [84]. A large retrospective review in Taiwan showed an increased risk, similar to that of hypertension, of incident CKD in those with newly diagnosed OSA [85].

OSA induced renal disease can be explained by two primary mechanisms, hypertension and intra renal hypoxia with glomerular hyperfiltration [77]. The renal medulla is particularly sensitive to hypoxia, triggering oxidative stress, systemic inflammation, and endothelial dysfunction and resulting in tubulointerstitial injury, which is the hallmark of CKD. Apnoeic episodes stimulate the sympathetic nervous and RAAS systems, leading to systemic and glomerular hypertension, vascular damage and arterial wall stiffness, culminating in renal ischaemia.

**Impact of therapy**

CPAP has been shown to positively impact renal haemodynamics in patients with normal renal function at baseline, suggesting a benefit in slowing renal injury [76]. However, the role of CPAP in attenuating the progression of renal impairment in OSA is uncertain with studies reporting differing results, and there are few studies focusing on patients with established CKD.

The ESADA cohort study reported a slower decline in eGFR in patients using fixed CPAP compared with auto-adjusting CPAP in patients without CKD [86]. CPAP treatment in patients with moderate to severe OSA has been reported to positively impact kidney filtration in the short term [77]. Another uncontrolled observational study reported a significant reduction in serum creatinine and increase in eGFR in males with AHI >20 after 3 months of CPAP [87]. A longer follow-up study again showed positive short term benefits but, after 8 years, patients with higher AHI had higher serum creatinine levels, despite CPAP treatment [74]. An RCT of patients with Stage 3 and 4 CKD showed no statistically significant difference in eGFR between CPAP and usual care over a 1 year follow-up, while demonstrating some improvement in renal function in those at a lower risk of CKD progression [88]. Furthermore, a post hoc analysis of 200 patients from the SAVE trial reported that CPAP treatment of OSA in patients with cardiovascular disease does not alter renal function or the occurrence of renal adverse events [89].

**Stroke**

SDB is common in patients after stroke. Whether OSA reflects a provoking factor by potentiating known vascular risk factors such as hypertension, or a consequence of stroke-related brain injury, remains unclear. With increasing research, it is evident that the complex relationship between stroke and sleep is bidirectional [90].

**OSA predisposing to stroke**

OSA is a risk factor for stroke and confers approximately a two-fold increase in stroke incidence [91]. A meta-analysis of six systemic reviews identified an increased occurrence of stroke in those with untreated OSA, even considering potential confounders such as age, BMI, diabetes and high BP [91]. The Sleep Heart Health Study prospectively demonstrated a direct relationship between OSA and subsequent risk of stroke [92]. Moreover, it reported a connection between OSA severity and stroke risk in younger men, with a rise of 6% for every unit rise between 5 and 25 events per hour. In the Wisconsin Cohort study, there was an increased stroke risk (OR 4.3) in those with an AHI >20 [93]. Initial studies identified 25% of strokes as occurring during sleep, suggesting a circadian influence on the pathophysiology [94]. The phenomenon of wake-up stroke led to a particular focus on REM sleep and highlighted arousal as a possible trigger. The Sleep Tight study reported that men with wake-up strokes had significantly higher AHI scores [95]. Dysautonomia, circadian activation of RAAS and fluctuations in BP result in changes in cerebral blood flow. This, in turn, stimulates intermediary mechanisms such as platelet aggregation, hypercoagulability and endothelial damage. Additionally, accelerated atherosclerosis, impaired glucose
tolerance and cardiac dysrhythmias, particularly refractory atrial fibrillation, are more common in untreated OSA, resulting in a higher risk of stroke. The presence of OSA has been reported to increase the risk of recurrent or repeated stroke [96].

**Impact of therapy**

CPAP’s role in patients with OSA is controversial, with variable results from cohort studies to date. Observational studies indicate a reduction in stroke risk in patients with OSA, particularly in treatment compliant patients [97]. RCTs suggested compliance ≥4 h with treatment may provide some benefit [98]. Although the SAVE trial reported no reduction in stroke rate with CPAP therapy [63], a more recent post hoc analysis of this trial identified self-reported snoring as a risk factor for incident stroke [99]. Potential benefits of treatment are more convincing and easier to demonstrate in OSA patients post-stroke despite a relative paucity of studies in this setting [100]. Post-stroke rehabilitation in untreated OSA can be adversely affected, especially with reduced executive function, attention, sleepiness and psychomotor ability. Randomised trials support an improvement in both short and long-term functional outcomes with CPAP therapy [101] while others report no difference in neurological outcome based on intention to treat analysis, although some improvement was observed in CPAP-compliant patients [102]. Treatment aims to target the alterations in cerebral autoregulation and to protect the ischaemic penumbra area. Many of these studies are limited by methods of measuring outcomes, including the unreliability of patient-reported symptoms post-stroke. Patient selection (stroke severity, disability, and complications such as delirium or depression), in addition to difficulty with recruitment and adherence, can confound results, thus contributing to inconsistent outcomes. Furthermore, it is likely that improvements in glycaemic and BP control also reduce the risk of recurrent stroke.

**Stroke predisposing to OSA**

The prevalence of OSA is high in stroke, with one-third of survivors documenting an AHI >30 [96, 103], although it is possible that stroke may unearth pre-existing OSA [104]. Post-stroke sleep architecture may impair breathing control mechanisms at a central level, but more specifically, stroke may adversely affect upper airway muscle function, thus increasing collapsibility. Further evidence for OSA as a consequence of stroke is the fall in frequency of events from the acute to the subacute phase of recovery. OSA is a predictor of poor outcome post-stroke, and has been associated with increased cerebrovascular morbidity, including worse functional and cognitive outcomes, and longer hospitalisation and rehabilitation times [105]. Patients with OSA presenting with acute stroke also tend to have higher National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale scores on discharge [106]. The mechanism through which these detrimental effects occur is proposed to be a further insult to the ischaemic penumbra by an arterial blood flow steal situation that has been described post-stroke, whereby apnoea-induced hypercapnia redirects blood flow from the already ischaemic region in a “reverse Robin Hood” phenomenon. A prospective study found 1.8 times increased risk of death in a 10-year follow-up of those with stroke and OSA [107].

**COPD**

COPD has a complex relationship with OSA with some factors such as hyperinflation being protective against OSA, whereas other factors such as fluid retention promoting OSA. These considerations likely explain at least some of the reported differences in the epidemiology of this relationship [108].

**COPD predisposing to OSA**

Most reports evaluating the relationship of COPD with OSA have focussed on COPD as a contributing factor for OSA. Data from the Sleep Heart Health Study found no increased prevalence of SDB in patients with mild COPD [109], although oxygen desaturations during sleep were more pronounced in patients with both disorders compared with those with either disorder alone. However, more recent studies have reported a relatively high level of OSA in patients with moderate-to-severe COPD [110, 111]. The reasons for these conflicting results are unclear but may reflect the different populations under investigation. It is notable that increasing BMI and smoking history positively correlate with the likelihood of OSA in patients with COPD [111].

COPD includes a spectrum of clinical phenotypes ranging from the hyperinflated patient with low BMI (predominant emphysema phenotype) to the patient with higher BMI and right HF (predominant chronic bronchitis phenotype). The predominant emphysema phenotype has a lower likelihood of OSA as demonstrated by a more negative critical closing pressure of the upper airway during sleep [112]. However, the predominant chronic bronchitis phenotype may predispose to OSA due to a higher BMI and a higher prevalence of right HF with fluid retention. Rostral fluid shift during sleep in the recumbent position predisposes to upper airway obstruction by airway narrowing similar to HF (figure 1) [66]. Data from the COPDGene study indicate that the chronic bronchitis phenotype has a higher prevalence of OSA even in the absence of differences in BMI and lung function [113]. Upper airway inflammation associated with cigarette smoking may also contribute to OSA [114] in addition to skeletal myopathy affecting the upper airway muscles.
OSA predisposing to COPD

Reports of OSA as a risk factor for COPD have produced varying findings [115]. Greenberg-Dotan et al. [116] reported a higher prevalence of COPD and asthma in patients with OSA compared with a matched control population, especially among females. However, Zhao et al. [117] reported a lower prevalence of COPD in subjects with SDB compared with those without SDB in a community-based study of 853 community-dwelling older men. OSA also appears to exacerbate lower airway inflammation in patients with COPD [118] and animal studies report that chronic intermittent hypoxia contributes to lung damage in mice by inducing inflammation and oxidative stress [119].

Thus, the epidemiological relationship of COPD and OSA and related outcomes remain an important topic for further research comparing different clinical phenotypes and across the age spectrum. Factors that impact the interrelationship between the two disorders are illustrated in figure 2.

Impact of therapy

Patients with COPD-OSA overlap treated with long-term CPAP have a survival similar to patients with COPD alone, whereas overlap patients not treated with CPAP have a higher mortality and rate of hospitalisation with acute exacerbations [120, 121]. These findings emphasise the importance of recognising co-existent OSA in patients with severe COPD so that optimum therapy can be selected.

Depression

Depression and OSA may exhibit similar symptoms, including poor concentration, memory and fatigue, which complicate their clinical assessment and diagnosis (figure 3). Sleep disturbance is a frequent self-reported symptom of depression, and may represent a predictive symptom for the later development of depression [122]. A more recent theory is that those with depression are at a higher risk of OSA later in life [123]. Proposed mechanisms underlying each process include sleep fragmentation, frequent arousals and intermittent hypoxic episodes resulting in cerebral hypoperfusion and neurotransmitter dysfunction. Despite biologic plausibility, there is little research in possible bidirectional relationships, and findings have been inconsistent.
A study of nearly 19,000 participants of all ages reported that in patients with OSA or depression, almost one-fifth also had the other disorder, supporting a mutual relationship [124]. A prospective study from Taiwan reported that patients with OSA had an increased risk of subsequent physician-diagnosed depression [125], and there was a reciprocal link with an increased risk of incident OSA at follow-up for those with depression at baseline, independent of sociodemographic factors and comorbidities.

**OSA predisposing to depression**

In clinical cohorts, the prevalence of depression in OSA ranges from 20–40% [126] and there appears to be an increased odds ratio of depression with increasing severity of SDB [127]. However, other smaller studies reported that the presence or severity of OSA were not independent predictors of depression scores or subsequent hospitalisation [128, 129].

**Impact of therapy**

A meta-analysis of 22 RCTs involving CPAP and mandibular advancement device (MAD) therapy of OSA reported a modest benefit and, more importantly, a clinically relevant improvement in depressive symptomatology using recognised depression scales [130]. The analysis demonstrated a dose-dependent...
response whereby those with worse depressive symptoms at the onset of treatment yielded the most benefit. Treatment of OSA with CPAP for 5 or more hours nightly for at least 3 months improved depressive symptoms, including suicidal ideation [131], which was independent of the use of antidepressants.

**Depression predisposing to OSA**
Depression as a potential cause of OSA has not been well studied. Prevalence reports indicate that 15% of psychiatric inpatients with major depressive disorder (MDD) have increased AHI on overnight polysomnography, and 18% of patients with MDD also met the diagnostic criteria for OSA [132, 133]. Another study found a higher prevalence of 39% and suggested that insomnia contributed to this increased prevalence [123]. The exclusion of diagnosed and probable patients with OSA strengthens the findings of this study.

**Impact of therapy**
A review of prospective studies looking at five different antidepressants found only two had a positive impact on reducing AHI but did not affect sleepiness or sleep quality [134]. Furthermore, undiagnosed OSA may worsen with some pharmacological treatments targeting depression, with weight gain as one potential factor [135]. Benzodiazepines can increase the frequency and duration of apnoeic events by affecting upper airway tone and alteration of the arousal threshold.

**Points for clinical practice and questions for future research**
- The association of comorbidity with OSA may be bidirectional and, thus, does not necessarily imply a causative association for OSA in the relationship.
- Comorbidities associated with fluid retention are especially likely to predispose to OSA by rostral distribution of fluid in the recumbent position.
- Clinicians involved in the care of patients with metabolic, cardiovascular, renal and neuropsychiatric disorders should be alert to the possibility that many of these disorders may predispose to OSA.
- Cross-sectional reports of independent associations of OSA and selected comorbidities do not imply causality, and greater emphasis should be placed in future research on prospective outcome studies to clarify the nature of such relationships.

**Conclusion**
OSA may occur in association with many comorbidities, some of which may represent risk factors for OSA by differing mechanisms. While there has been substantial research on the role of OSA as an independent risk factor for comorbidity, the reverse relationship has been less well studied and represents an important area for future research. The authors’ assessment of the putative bidirectional relationships between OSA and comorbidities is given in figure 4.

Provenance: Commissioned article, peer reviewed.

Conflict of interest: M. Gleeson has nothing to disclose. W.T. McNicholas has nothing to disclose.

**References**

1. Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. *Nat Rev Dis Primers* 2015; 1: 1–20.
2. McNicholas WT. Obstructive sleep apnoea and comorbidity – an overview of the association and impact of continuous positive airway pressure therapy. *Expert Rev Respir Med* 2019; 13: 251–261.
3. McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. *Eur Respir J* 2007; 29: 156–178.
4. Castro-Grattoni AL, Alvarez-Buvé R, Torres M, et al. Intermittent hypoxia-induced cardiovascular remodeling is reversed by normoxia in a mouse model of sleep apnea. *Chest* 2016; 149: 1400–1408.
5. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia—revisited—the bad ugly and good: implications to the heart and brain. *Sleep Med Rev* 2015; 20: 27–45.
6. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. *Eur Respir J* 2009; 33: 1195–1205.
7. Vgontzas AN, Gaines J, Ryan S, et al. CrossTalk proposal: metabolic syndrome causes sleep apnoea. *J Physiol* 2016; 594: 4687–4690.
8. Crinion SJ, Ryan S, McNicholas WT. Obstructive sleep apnoea as a cause of nocturnal nondipping blood pressure: recent evidence regarding clinical importance and underlying mechanisms. *Eur Respir J* 2017; 49: 1601818.
9. Murphy AM, Thomas A, Crinion SJ, et al. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. *Eur Respir J* 2017; 49: 1601731.
McEvoy RD, Kohler M. Con: continuous positive airway pressure and cardiovascular prevention.

Drager LF, Togeiro SM, Polotsky VY, Phillips CL, Hoyos CM, Yee BJ, Martinez-Garcia MA, Campos-Rodriguez F, Javaheri S, Peppard PE, Young T, Palta M, Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnoea.

Resta O, Foschino-Barbaro MP, Legari G, Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive sleep apnea.

Schiza S, Lévy P, Martinez-Garcia MA, et al. “Syndrome Z”: the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998; 53: Suppl. 3, S25–S58.

Drager LF, Togeiro SM, Polotsky VY, Phillips CL, Hoyos CM, Yee BJ, Martinez-Garcia MA, Campos-Rodriguez F, Javaheri S, Peppard PE, Young T, Palta M, Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnoea. J Physiol 2016; 594: 4691–4694.

Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnoea. Eur Respir J 1995; 8: 1161–1178.

Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive sleep apnea – Clinical significance of weight loss. Sleep Med Rev 2013; 17: 321–329.

Resta O, Foschino-Barbaro MP, Legari G, et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001; 25: 669–675.

Fritscher LG, Mottin CC, Canani S, et al. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg 2007; 17: 95–99.

Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight loss on obstructive sleep apnea severity, ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med 2021; 203: 221–229.

Sutherland K, Phillips CL, Yee BJ, et al. Maxillomandibular volume influences the relationship between weight loss and improvement in obstructive sleep apnea. Sleep 2016; 39: 43–49.

Borel AL, Leblanc X, Almeras N, et al. Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity. Thorax 2012; 67: 735–741.

Redenius R, Murphy C, O’Neill E, et al. Does CPAP lead to change in BMI? J Clin Sleep Med 2008; 4: 205–209.

Neutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. Chest 2017; 152: 1070–1086.

Kent BD, Grote L, Ryan S, et al. Diabetes mellitus prevalence and control in sleep-disordered breathing: the European Sleep Apnea Cohort (ESADA) Study. Chest 2014; 146: 982–990.

Kent BD, Grote L, Bonsignore MR, et al. Sleep apnoea severity independently predicts glycaemic health in nondiabetic subjects: the ESADA study. Eur Respir J 2014; 44: 130–139.

Lindberg E, Theorell-Haglöw J, Svensson M, et al. Sleep apnea and glucose metabolism: a long-term follow-up in a community-based sample. Chest 2012; 142: 935–942.

Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnoea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med 2014; 190: 218–225.

Chirinos JA, Gurubhagavatula I, Teff K, et al. CPAP, weight loss or both for obstructive sleep apnea. N Engl J Med 2014; 370: 2265–2275.

Ioachimescu OC, Anthony J, Constantin T, et al. VAMONOS (Veterans Affairs’ Metabolism, Obstructed and Non-Obstructed Sleep) study: effects of CPAP Therapy on glucose metabolism in patients with obstructive sleep apnea. J Clin Sleep Med 2017; 13: 455–466.

Subramanian A, Adderley NJ, Tracy A, et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care 2019; 42: 954–963.

Huang T, Lin BM, Stamper MJ, et al. A Population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective U.S. cohorts. Diabetes Care 2018; 41: 2111–2119.

Parati G, Lombardi C, Hedner J, et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J 2013; 41: 523–538.

Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829–1836.

Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–1384.

Xia W, Huang Y, Peng B, et al. Relationship between obstructive sleep apnoea syndrome and essential hypertension: a dose-response meta-analysis. Sleep Med 2018; 47: 11–18.

Baguet JP, Hammer L, Lévy P, et al. Night-time and diastolic hypertension are common and underestimated conditions in newly diagnosed apnoeic patients. J Hypertens 2005; 23: 521–527.

Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health 2018; 8: 010405.
Bouloukaki I, Grote L, McNicholas WT, et al. Mild obstructive sleep apnea increases hypertension risk, challenging traditional severity classification. *J Clin Sleep Med* 2020; 16: 898–899.

Vgontzas AN, Li Y, He F, et al. Mild-to-moderate sleep apnea is associated with incident hypertension: age effect. *Sleep* 2019; 42: ezy265.

Tamisier R, Lévy P. Management of hypertension in obstructive sleep apnoea: predicting blood pressure reduction under continuous positive airway pressure. *Eur Respir J* 2017; 50: 1701822.

Pengo MF, Soranna D, Giontella A, et al. Obstructive sleep apnoea treatment and blood pressure: which phenotypes predict a response? A systematic review and meta-analysis. *Eur Respir J* 2020; 55: 1901945.

Lévy P, McNicholas WT. Sleep apnoea and hypertension: time for recommendations. *Eur Respir J* 2013; 41: 505–506.

Lombardi C, Pengo MF, Parati G. Systemic hypertension in obstructive sleep apnea. *J Thorac Dis* 2018; 10: Suppl. 34, S4231–S4243.

Khurshid K, Yabes J, Weiss PM, et al. Coronary heart disease and heart failure: the sleep heart health study. *Circulation* 2013; 128: 2116–2122.

Khayat R, Jarjoura D, Porter K, et al. Obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; 366: 1046–1053.

Doherty LS, Kiely JL, Swan V, et al. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest* 2005; 127: 2076–2084.

Mckevoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med* 2016; 375: 919–931.

Ferrier K, Campbell A, Yee B, et al. Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. *Chest* 2005; 128: 2116–2122.

Schulz R, Blau A, Bürgel J, et al. Sleep apnoea in heart failure. *Eur Respir J* 2007; 29: 1201–1205.

White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. *J Physiol* 2013; 591: Pt 5, 1179–1193.

Kasai T, Arcand J, Allard JP, et al. Relationship between sodium intake and sleep apnea in patients with heart failure. *J Am Coll Cardiol* 2011; 58: 1970–1974.

Redolfi S, Arnulf I, Pottier M, et al. Attenuation of obstructive sleep apnea by compression stockings in subjects with venous insufficiency. *Am J Respir Crit Care Med* 2011; 184: 1062–1066.

Fiori CZ, Martinez D, Montanari CC, et al. Diuretic or sodium-restricted diet for obstructive sleep apnea – a randomized trial. *Sleep* 2018; 41: 89016.

Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest* 2007; 132: 440–446.
Tang SC, Lam B, Lai AS, Ahmed SB, Ronksley PE, Hemmelgarn BR, Lyons OD, Chan CT, Yadollahi A, Santos RS, Motwani SS, Elias RM. Chronic kidney disease and sleeping disordered breathing (SDB).

Lyons OD, Inami T, Perger E, Hanly P. Sleep apnea and daytime sleepiness in end-stage renal disease.

Abuyassin B, Sharma K, Ayas NT, Stanchina ML, Ellison K, Malhotra A, Nicholl DDM, Ahmed SB, Loewen AHS, Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis.

Haba-Rubio J, Vujica J, Franc Y, et al. Effect of CPAP treatment of sleep apnea on clinical prognosis after ischemic stroke: an observational study.

Parra O, Sánchez-Armengol Á, Capote F, et al. Efficacy of continuous positive airway pressure treatment on 5-year survival in patients with ischemic stroke and obstructive sleep apnea: a randomized controlled trial.

Gupta A, Shukla G, Afsar M, et al. Role of positive airway pressure therapy for obstructive sleep apnea in patients with stroke: a randomized controlled trial.
Povitz M, Bolo CE, Heitman SJ, Kendzerska T, Gershon AS, Hawker GA, Bixler EO, Gaines J, Vgontzas AN. Obstructive sleep apnoea and depression: is there an association? Arch Intern Med 2016; 176: 158–168.

Pan ML, Tsao HM, Hsu CC, Seiler A, Camilo M, Korostovtseva L, Brill AK, Horvath T, Seiler A, Alexiev F, Brill AK, Ott SR, et al. Sleep-disordered breathing and stroke: chicken or egg? J Thorac Dis 2018; 10: Suppl. 34, S4244–S4552.

Kaneko Y, Hajek VE, Zivanovic V, et al. Relationship of sleep apnea to functional capacity and length of hospitalization following stroke. Sleep 2003; 26: 293–297.

Menon D, Sukumaran S, Varma R, et al. Impact of obstructive sleep apnea on neurological recovery after ischemic stroke: a prospective study. Acta Neurol Scand 2017; 136: 419–426.

Sahlin C, Sandberg O, Gustafson Y, et al. Integrating the overlap of obstructive lung disease and obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2017; 49: 1020–1031.

Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167: 7–14.

Soler X, Gaio E, Powell FL, et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc 2015; 12: 1219–1225.

Steveling EH, Clarensbach CF, Miedinger D, et al. Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respir Res 2018; 18: 451–457.

Biselli P, Grossman PR, Kirkness JP, et al. The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep. J Appl Physiol (1985) 2015; 119: 266–271.

Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011; 140: 626–633.

Renner B, Mueller CA, Shephard A. Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat). Inflamm Res 2012; 61: 1041–1052.

Ioachimescu OC, Teodorescu M. Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respir Res 2013; 18: 421–431.

Greenberg-Dotan S, Reuveni H, Tal A, et al. Increased prevalence of obstructive lung disease in patients with obstructive sleep apnea. Sleep Breath 2014; 18: 69–75.

Zhao YY, Blackwell T, Ensrud KE, et al. Sleep apnea and obstructive airway disease in older men: outcomes of sleep disorders in older men study. Sleep 2016; 39: 1343–1351.

Wang Y, Hu K, Liu K, et al. Obstructive sleep apnea exacerbates airway inflammation in patients with chronic obstructive pulmonary disease. Sleep Med 2015; 16: 1123–1130.

Tuleta I, Stöckigt F, Juergens UR, et al. Intermittent hypoxia contributes to the lung damage by increased oxidative stress, inflammation, and disbalance in protease/antiprotease system. Lung 2016; 194: 1015–1020.

Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. Am J Respir Crit Care Med 2010; 182: 325–331.

Machado M-CL, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35: 132–137.

Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med 2019; 23: 2224–2232.

Ong JC, Gress JL, San Pedro-Salcedo MG, et al. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J Psychosom Res 2009; 67: 135–141.

Ohayon MM. The effects of breathing-related sleep disorders on mood disturbances in the general population. J Clin Psychiatry 2003; 64: 1195–1200, quiz, 274–6.

Pan ML, Tsao HM, Hsu CC, et al. Bidirectional association between obstructive sleep apnea and depression: a population-based longitudinal study. Medicine (Baltimore) 2016; 95: e4833.

Bixler EO, Gaines J, Vgontzas AN. Obstructive sleep apnoea and depression: is there an association? Eur Respir J 2017; 49: 1700858.

Peppard PE, Szko-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med 2006; 166: 1709–1715.

Sforza E, Saint Martin M, Barthélémy JC, et al. Mood disorders in healthy elderly with obstructive sleep apnea: a gender effect. Sleep Med 2016; 19: 57–62.

Kendzerska T, Gershon AS, Hawker GA, et al. Obstructive sleep apnoea is not a risk factor for incident hospitalised depression: a historical cohort study. Eur Respir J 2017; 49: 1601361.

Povitz M, Bolo CE, Heitman SJ, et al. Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med 2014; 11: e1001762.
131 Edwards C, Mukherjee S, Simpson L, et al. Depressive symptoms before and after treatment of obstructive sleep apnea in men and women. J Clin Sleep Med 2015; 11: 1029–1038.

132 Reynolds CF, Coble PA, Spiker DG, et al. Prevalence of sleep apnea and nocturnal myoclonus in major affective disorders: clinical and polysomnographic findings. J Nerv Ment Dis 1982; 170: 565–567.

133 Jehan S, Auguste E, Pandi-Perumal SR, et al. Depression, obstructive sleep apnea and psychosocial health. Sleep Med Disord 2017; 1: 000012.

134 AbdelFattah MR, Jung SW, Greenspan MA, et al. Efficacy of antidepressants in the treatment of obstructive sleep apnea compared to placebo. A systematic review with meta-analyses. Sleep Breath 2020; 24: 443–453.

135 Lu B, Budhiraja R, Parthasarathy S. Sedating medications and undiagnosed obstructive sleep apnea: physician determinants and patient consequences. J Clin Sleep Med 2005; 1: 367–371.